Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGLS4326 in ADPKD
NCT04536688Phase 1Completed
- Sponsor
- Regulus Therapeutics
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGLS4326 in autosomal dominant polycystic kidney disease (ADPKD) (3 cohorts), sponsored by Regulus Therapeutics. Primary endpoint: Changes in primary biomarker levels from baseline at Day 44. Started Oct 2020; status: completed.
02
Drugs
RGLS4326
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04536688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536688.